Active, not recruitingPhase 3NCT05029635
Phase III Study on HMPL-523 for Treatment of ITP
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hutchison Medipharma Limited
- Principal Investigator
- Renchi Yang, professoroffices director
- Intervention
- HMPL-523(drug)
- Enrollment
- 272 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2021 – 2025
Study locations (30)
- The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
- The First Affiliated hospital of USTC, Hefei, Anhui, China
- Beijing Chaoyang Hospital of Capital Medical University, Beijing, Beijing Municipality, China
- Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
- People's Hospital of Peking University, Beijing, Beijing Municipality, China
- Fujian Medical University Union Hospital, Fuzhou, Fujian, China
- Lanzhou University Second Hospital, Lanzhou, Gansu, China
- Guangdong General Hospital, Guangzhou, Guangdong, China
- Southern Hospital of Southern Medical University, Guangzhou, Guangdong, China
- The Second People's Hospital Of Shenzhen, Shenzhen, Guangdong, China
- The First Affiliated Hospital Of GuangXi Medical University, Nanning, Guangxi, China
- The First Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
- Affiliated Hospital of North China University of Technology, Tangshan, Hebei, China
- First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05029635 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation